| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 19 | 2017 | 424 | 2.960 |
Why?
|
| Coronary Artery Bypass | 12 | 2017 | 100 | 2.560 |
Why?
|
| Heart Valve Prosthesis Implantation | 8 | 2018 | 41 | 2.420 |
Why?
|
| Heart Valve Prosthesis | 5 | 2018 | 53 | 2.270 |
Why?
|
| Aortic Valve Stenosis | 5 | 2018 | 29 | 2.160 |
Why?
|
| Aortic Valve | 4 | 2018 | 48 | 1.940 |
Why?
|
| Bioprosthesis | 4 | 2018 | 55 | 1.840 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2018 | 24 | 1.370 |
Why?
|
| Coronary Artery Disease | 12 | 2017 | 377 | 1.370 |
Why?
|
| Thrombolytic Therapy | 6 | 2013 | 59 | 1.280 |
Why?
|
| Vascular Surgical Procedures | 3 | 2017 | 91 | 1.260 |
Why?
|
| Stents | 7 | 2018 | 171 | 1.140 |
Why?
|
| Bone Marrow Transplantation | 12 | 2017 | 65 | 1.130 |
Why?
|
| Treatment Outcome | 27 | 2018 | 3128 | 1.120 |
Why?
|
| Myocardial Reperfusion | 4 | 2012 | 10 | 1.100 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2017 | 137 | 1.050 |
Why?
|
| Humans | 72 | 2020 | 29556 | 0.970 |
Why?
|
| Time Factors | 17 | 2020 | 2014 | 0.950 |
Why?
|
| Risk Assessment | 7 | 2020 | 1329 | 0.930 |
Why?
|
| Heart-Assist Devices | 5 | 2011 | 19 | 0.870 |
Why?
|
| Coronary Disease | 4 | 2013 | 202 | 0.850 |
Why?
|
| Heart Transplantation | 4 | 2011 | 26 | 0.830 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2017 | 85 | 0.800 |
Why?
|
| Electrocardiography | 8 | 2015 | 571 | 0.790 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 43 | 0.770 |
Why?
|
| Disease Management | 5 | 2015 | 114 | 0.750 |
Why?
|
| Catheterization, Peripheral | 2 | 2017 | 25 | 0.700 |
Why?
|
| Thrombosis | 2 | 2017 | 60 | 0.700 |
Why?
|
| Aged | 25 | 2019 | 9590 | 0.690 |
Why?
|
| Shock, Cardiogenic | 2 | 2011 | 7 | 0.680 |
Why?
|
| Coronary Angiography | 6 | 2016 | 139 | 0.670 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 72 | 0.660 |
Why?
|
| Retrospective Studies | 14 | 2019 | 3144 | 0.660 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 77 | 0.660 |
Why?
|
| Female | 34 | 2019 | 18379 | 0.640 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 177 | 0.630 |
Why?
|
| Risk Factors | 11 | 2020 | 3600 | 0.620 |
Why?
|
| Tricuspid Valve | 1 | 2017 | 5 | 0.620 |
Why?
|
| Fibrinolytic Agents | 3 | 2013 | 70 | 0.610 |
Why?
|
| Foramen Ovale, Patent | 1 | 2017 | 7 | 0.610 |
Why?
|
| Femoral Artery | 1 | 2017 | 44 | 0.600 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 61 | 0.570 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 8 | 0.570 |
Why?
|
| Cardiology | 7 | 2016 | 83 | 0.570 |
Why?
|
| Iliac Artery | 2 | 2014 | 46 | 0.570 |
Why?
|
| Echocardiography | 2 | 2016 | 141 | 0.570 |
Why?
|
| Middle Aged | 27 | 2019 | 10936 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 4 | 2015 | 376 | 0.560 |
Why?
|
| Male | 32 | 2019 | 18012 | 0.550 |
Why?
|
| Balloon Occlusion | 3 | 2014 | 29 | 0.510 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 3764 | 0.510 |
Why?
|
| Prosthesis Design | 4 | 2018 | 87 | 0.510 |
Why?
|
| Heart Valve Prolapse | 1 | 2014 | 1 | 0.510 |
Why?
|
| Evidence-Based Medicine | 8 | 2015 | 209 | 0.470 |
Why?
|
| Myocardial Ischemia | 6 | 2015 | 85 | 0.460 |
Why?
|
| Ticlopidine | 1 | 2013 | 17 | 0.450 |
Why?
|
| Steroids | 1 | 2013 | 36 | 0.440 |
Why?
|
| Coronary Vessels | 3 | 2016 | 151 | 0.440 |
Why?
|
| Aspirin | 1 | 2013 | 66 | 0.440 |
Why?
|
| Radial Artery | 1 | 2012 | 15 | 0.430 |
Why?
|
| Specialization | 1 | 2012 | 30 | 0.430 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 1058 | 0.420 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2011 | 71 | 0.400 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 16 | 0.400 |
Why?
|
| American Heart Association | 5 | 2016 | 84 | 0.390 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2011 | 4 | 0.390 |
Why?
|
| Life Support Care | 1 | 2011 | 15 | 0.390 |
Why?
|
| Heart Arrest | 1 | 2011 | 39 | 0.380 |
Why?
|
| Life Support Systems | 1 | 2010 | 4 | 0.380 |
Why?
|
| Adult | 17 | 2019 | 8528 | 0.380 |
Why?
|
| Coronary Circulation | 2 | 2012 | 30 | 0.370 |
Why?
|
| Bone Marrow Cells | 4 | 2016 | 115 | 0.370 |
Why?
|
| Hemorrhage | 4 | 2017 | 94 | 0.350 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2009 | 3 | 0.350 |
Why?
|
| Asthma | 1 | 2013 | 397 | 0.350 |
Why?
|
| Hemodynamics | 4 | 2018 | 148 | 0.350 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2009 | 19 | 0.350 |
Why?
|
| Patient Selection | 5 | 2013 | 257 | 0.340 |
Why?
|
| Graft Rejection | 3 | 2011 | 149 | 0.330 |
Why?
|
| Heart Failure | 5 | 2018 | 576 | 0.330 |
Why?
|
| Operating Rooms | 1 | 2009 | 32 | 0.330 |
Why?
|
| Hypertension, Pulmonary | 3 | 2014 | 23 | 0.320 |
Why?
|
| Time and Motion Studies | 1 | 2008 | 6 | 0.320 |
Why?
|
| Total Quality Management | 1 | 2008 | 19 | 0.310 |
Why?
|
| Hospitals, University | 1 | 2008 | 23 | 0.310 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 28 | 0.300 |
Why?
|
| Recovery of Function | 3 | 2018 | 190 | 0.300 |
Why?
|
| Sirolimus | 1 | 2007 | 35 | 0.300 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2006 | 1 | 0.290 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2006 | 7 | 0.290 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 94 | 0.280 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 4 | 2012 | 10 | 0.280 |
Why?
|
| Medication Therapy Management | 4 | 2012 | 12 | 0.270 |
Why?
|
| Ventricular Function, Left | 6 | 2016 | 198 | 0.270 |
Why?
|
| Coronary Vasospasm | 1 | 2005 | 4 | 0.270 |
Why?
|
| United States | 8 | 2016 | 3693 | 0.270 |
Why?
|
| Vasoconstriction | 1 | 2005 | 40 | 0.260 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2014 | 7 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 864 | 0.240 |
Why?
|
| Clinical Protocols | 3 | 2012 | 95 | 0.240 |
Why?
|
| Thrombectomy | 2 | 2015 | 58 | 0.230 |
Why?
|
| Emergency Medical Services | 4 | 2012 | 158 | 0.230 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 525 | 0.230 |
Why?
|
| Saphenous Vein | 2 | 2017 | 20 | 0.220 |
Why?
|
| Radiography | 2 | 2014 | 355 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2016 | 1701 | 0.220 |
Why?
|
| Myocardium | 2 | 2010 | 170 | 0.220 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 9 | 0.220 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 9 | 0.210 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 81 | 0.210 |
Why?
|
| Interferon-gamma | 1 | 2002 | 51 | 0.210 |
Why?
|
| Stroke Volume | 6 | 2017 | 282 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2002 | 62 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 100 | 0.200 |
Why?
|
| Double-Blind Method | 8 | 2017 | 507 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2124 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2011 | 40 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 471 | 0.190 |
Why?
|
| Equipment Design | 3 | 2011 | 167 | 0.180 |
Why?
|
| Punctures | 2 | 2017 | 32 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2010 | 50 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 203 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 22 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 840 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 150 | 0.170 |
Why?
|
| Spinal Fusion | 1 | 2019 | 42 | 0.170 |
Why?
|
| Decompression, Surgical | 1 | 2019 | 53 | 0.160 |
Why?
|
| Lung Injury | 1 | 2019 | 64 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 74 | 0.160 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 98 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2019 | 99 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 156 | 0.160 |
Why?
|
| Antigens, CD34 | 2 | 2016 | 54 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2019 | 180 | 0.150 |
Why?
|
| Septal Occluder Device | 1 | 2017 | 4 | 0.150 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2017 | 22 | 0.150 |
Why?
|
| Regeneration | 1 | 2019 | 168 | 0.150 |
Why?
|
| Colony-Forming Units Assay | 2 | 2014 | 17 | 0.150 |
Why?
|
| Lung | 1 | 2019 | 237 | 0.150 |
Why?
|
| Incidence | 1 | 2020 | 1127 | 0.140 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 39 | 0.140 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 235 | 0.140 |
Why?
|
| Young Adult | 3 | 2019 | 2431 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2017 | 171 | 0.140 |
Why?
|
| Length of Stay | 1 | 2017 | 296 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2017 | 333 | 0.140 |
Why?
|
| North Carolina | 1 | 2020 | 1430 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2015 | 37 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 110 | 0.130 |
Why?
|
| Stem Cells | 2 | 2015 | 295 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2016 | 150 | 0.130 |
Why?
|
| Vascular Resistance | 1 | 2014 | 28 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 49 | 0.120 |
Why?
|
| Device Removal | 1 | 2014 | 31 | 0.120 |
Why?
|
| Genomics | 2 | 2012 | 82 | 0.120 |
Why?
|
| Cell Separation | 2 | 2012 | 87 | 0.120 |
Why?
|
| Vasodilation | 1 | 2014 | 87 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 23 | 0.120 |
Why?
|
| Ependymoma | 1 | 2014 | 5 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2013 | 27 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2014 | 77 | 0.120 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2014 | 110 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 58 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2013 | 63 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 42 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2014 | 54 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 40 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2014 | 674 | 0.110 |
Why?
|
| Proteins | 1 | 2014 | 141 | 0.110 |
Why?
|
| Fluoroscopy | 1 | 2012 | 39 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 247 | 0.110 |
Why?
|
| Mutation | 2 | 2012 | 475 | 0.110 |
Why?
|
| Critical Illness | 1 | 2013 | 88 | 0.110 |
Why?
|
| Regenerative Medicine | 2 | 2012 | 192 | 0.100 |
Why?
|
| Retinoblastoma | 1 | 2012 | 10 | 0.100 |
Why?
|
| Neuregulin-1 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 9 | 0.100 |
Why?
|
| Tennessee | 2 | 2011 | 97 | 0.100 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2012 | 35 | 0.100 |
Why?
|
| Hemostatic Techniques | 1 | 2011 | 7 | 0.100 |
Why?
|
| Femoral Vein | 1 | 2011 | 10 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 80 | 0.100 |
Why?
|
| Intraoperative Care | 2 | 2009 | 48 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 101 | 0.100 |
Why?
|
| Survival Rate | 2 | 2011 | 797 | 0.100 |
Why?
|
| Transplantation, Autologous | 4 | 2012 | 78 | 0.100 |
Why?
|
| Suture Techniques | 1 | 2011 | 56 | 0.100 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2010 | 5 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2016 | 2046 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2010 | 26 | 0.090 |
Why?
|
| Catheterization | 1 | 2010 | 58 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2010 | 57 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2010 | 17 | 0.090 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 11 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 99 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 1080 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 165 | 0.090 |
Why?
|
| Venous Pressure | 1 | 2009 | 9 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2009 | 35 | 0.080 |
Why?
|
| Vascular Patency | 1 | 2009 | 68 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 129 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 151 | 0.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2008 | 11 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1225 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2010 | 166 | 0.080 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 6 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 32 | 0.080 |
Why?
|
| Acute Disease | 2 | 2014 | 239 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 676 | 0.080 |
Why?
|
| Animals | 5 | 2019 | 7339 | 0.080 |
Why?
|
| Research Design | 4 | 2010 | 289 | 0.080 |
Why?
|
| Heparin | 1 | 2008 | 75 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 533 | 0.070 |
Why?
|
| Constriction | 1 | 2006 | 12 | 0.070 |
Why?
|
| Algorithms | 1 | 2009 | 468 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2006 | 25 | 0.070 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 38 | 0.070 |
Why?
|
| Endothelins | 1 | 2005 | 4 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2005 | 13 | 0.070 |
Why?
|
| E-Selectin | 1 | 2005 | 20 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2005 | 18 | 0.070 |
Why?
|
| Serotonin | 1 | 2005 | 35 | 0.070 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2006 | 21 | 0.070 |
Why?
|
| Mice | 3 | 2019 | 2387 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 448 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2008 | 314 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 294 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2007 | 1172 | 0.060 |
Why?
|
| Angiopoietin-1 | 1 | 2003 | 6 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2003 | 15 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2014 | 20 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 27 | 0.060 |
Why?
|
| Receptors, CXCR3 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokine CXCL9 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokine CXCL11 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2002 | 2 | 0.050 |
Why?
|
| Rabbits | 1 | 2003 | 186 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 107 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 299 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2014 | 61 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 366 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 113 | 0.050 |
Why?
|
| Cell Line | 2 | 2014 | 456 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 139 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2012 | 22 | 0.050 |
Why?
|
| Cell Survival | 2 | 2012 | 278 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2012 | 18 | 0.050 |
Why?
|
| Interdisciplinary Communication | 2 | 2011 | 53 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2002 | 523 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2013 | 372 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 796 | 0.040 |
Why?
|
| Spondylolisthesis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Spinal Stenosis | 1 | 2019 | 11 | 0.040 |
Why?
|
| Scoliosis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 39 | 0.040 |
Why?
|
| Adolescent | 2 | 2019 | 3284 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2019 | 55 | 0.040 |
Why?
|
| Rats | 1 | 2003 | 1609 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 910 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 249 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 9 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2010 | 489 | 0.040 |
Why?
|
| Microcirculation | 1 | 2017 | 62 | 0.040 |
Why?
|
| Sepsis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 196 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2017 | 15 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2017 | 108 | 0.040 |
Why?
|
| Polymers | 1 | 2017 | 59 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 11 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2015 | 50 | 0.030 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 24 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 116 | 0.030 |
Why?
|
| China | 1 | 2014 | 44 | 0.030 |
Why?
|
| Dehydration | 1 | 2013 | 7 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2014 | 47 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 68 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2014 | 95 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 54 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 148 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 255 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 252 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2014 | 109 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 876 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 174 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 643 | 0.030 |
Why?
|
| Smoking | 1 | 2016 | 441 | 0.030 |
Why?
|
| Lipids | 1 | 2014 | 215 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2012 | 13 | 0.030 |
Why?
|
| Preservation, Biological | 1 | 2012 | 1 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 2012 | 2 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2012 | 19 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 2012 | 4 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2012 | 8 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2012 | 11 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Transportation | 1 | 2012 | 14 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 735 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2012 | 3 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 13 | 0.030 |
Why?
|
| Automation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Genes, ras | 1 | 2012 | 27 | 0.030 |
Why?
|
| Injections | 1 | 2012 | 61 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 37 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 494 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cell Death | 1 | 2012 | 74 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.030 |
Why?
|
| Histones | 1 | 2012 | 49 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 96 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 72 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 114 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2012 | 54 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 62 | 0.020 |
Why?
|
| Phlebography | 1 | 2011 | 26 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 139 | 0.020 |
Why?
|
| Genome, Human | 1 | 2012 | 129 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 104 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 116 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 228 | 0.020 |
Why?
|
| Automation, Laboratory | 1 | 2010 | 3 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 8 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 51 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 51 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1372 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 38 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 252 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 23 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 173 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 14 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 14 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 124 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 173 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 93 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2010 | 53 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 85 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 73 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 918 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 427 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2009 | 4 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2009 | 9 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1081 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 23 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 350 | 0.020 |
Why?
|
| Diastole | 1 | 2009 | 91 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 270 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 21 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 588 | 0.020 |
Why?
|
| Sternum | 1 | 2006 | 13 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 75 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2234 | 0.020 |
Why?
|